medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2015, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2015; 31 (2)

Polycythemia Vera at Jak age: brief analysis of the diagnosis after its introduction

Fernández DN, Martínez FD, Román TR, Amor VAM, Fundora ST, Macía PI, Hernández RL

Language: Spanish
References: 29
Page: 127-137
PDF size: 143.00 Kb.


ABSTRACT

Introduction: Polycythemia vera is a BCR/ABL negative myeloproliferative neoplasm in which the JAK2V617F mutation has been described in more than 90 % of cases. At the Institute of Hematology and Immunology determination of this mutation was introduced since the second half of 2008.
Objectives: to identify the percentage of positive patients for the JAK2V617F mutation and correlate this with the remaining variables possible to be studied in Cuba.
Methods: a descriptive study that included 45 patients, 15 previously diagnosed and 30 of new diagnosis, was carried out. All patients were evaluated according to 2001 and 2008 WHO criteria, with the following variables: demonstrated erythrocytosis, absence of secondary causes, visceromegaly, results of hemogram, bone marrow biopsy at diagnosis and molecular study.
Results: mutation was positive in 86,6 % (n = 39) of the patients with confirmed diagnosis by both WHO criteria. Two patients were considered unclassificable myeloproliferative neoplasms. Age was smaller in patients negative for the mutation (p = 0.03). The presence of the mutation was related to slightly superior leukocyte count, significant thrombocytosis (p = 0,000) and larger morphological changes in bone marrow histology.
Conclusions: these results show that it is possible to make the diagnosis of PV with the use of 2001 WHO criteria, but the molecular testing leads to an accurate diagnosis and contributes to reduce the rate of error. However, an objective review of current criteria might guarantee an accurate diagnosis in any place of the world.


REFERENCES

  1. Kremyanskaya M, Najfeld V, Mascarenhas J, Hoffman R. The polycythemias. In: Hoffman R, Benz EJ Jr., Silberstein LE, Heslop HE, Weitz JI, eds. Hematology basic principles and practice. 6th ed. Philadelphia: Elsevier Saunders; 2013.p. 988-1033.

  2. Fernández-Jiménez MC, Murga MJ, Remacha AF. Clasificación y diagnóstico de las eritrocitosis. Haematologica/edición española. 2010;95(Extra 1):423-8.

  3. Chen E, Beer P, Godfrey A, Ortmann C, Lee J, Costa-Pereira A, et al. Distinct clinical phenotypes associated with JAK2V617F reflect diferential STAT1 signaling. Cancer Cell. 2010 Nov;18(5):524-35. doi: 10.1016/jccr.2010.10.013.

  4. Roda P, Ferrari A, Tang X, Erlich P, Eisenhower C, Patel MD et al. Determination of accuracy of polycythemia vera diagnoses and use of the JAK2V617F test in the diagnostic scheme. Ann Hematol. 2014 Sep;93(9):1467-72. doi: 10.1007/s00277- 014-2068-2.

  5. Muxí PJ, Oliver AC. JAK-2 Positive Myeloproliferative Neoplasms. Curr Treat Options Oncol. 2014 Jun;15(2):147-56. doi: 10.1007/s11864-014-0279-3.

  6. Ugo V, Tondeur S, Menot ML, Bonnin N, Le Gac G, Tonetti C, et al. Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients. PLoS One. 2010;5(1):e8893. doi: 10.1371/journal.pone.0008893.

  7. Vardinman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul;114(5):937-51. doi: 10.1182/blood-2009-03-209262.

  8. Fernández Delgado N, Fundora Sarraff T, Macias Pérez I. Policitemia vera. Experiencias en el diagnóstico y tratamiento en el Instituto de Hematología e Inmunología. Rev Cubana Hematol Inmunol Hemoter. 2011:27(1):77-90.

  9. Means R. JAK2 V617F and the evolving paradigm of polycythemia vera. Korean J Hematol. 2010 Jun;45(2):90–4. doi: 10.5045/kjh.2010.45.2.90.

  10. Caires dos Santos L, Correa da Costa J, Pereira N, Cerutti J, Regis da Silva M, et al. Cytogenetic, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia Rev Bras Hemato. Hemoter. 2011; 33(6):417-24. DOI: 10.5581/1516-8484.20110116.

  11. Ruíz-Argüelles G, Ruíz-Delgado G, Ruíz-Reyes G. Síndromes mieloproliferativos crónicos. En: Palomo I, Pereira J, Palma J, eds. Hematología: Fisiopatología y Diagnóstico. Talca: Universidad de TALCA; 2005.p.320-32.

  12. Scott LM. The JAK2 exon 12 mutations: A comprehensive review. Am J Hematol. 2011 Aug;86(8):668-76. doi: 10.1002/ajh.22063.

  13. González García C, Funes Vera C, Blanquer Blanquer M, Moraleda Jiménez JM. Síndromes mieloproliferativos Medicine. 2012;11(21):1289-97.

  14. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Chronic Myeloproliferative Neoplasias. Survival and prognosis among 1545 patient with contemporary polycythemia vera: an international study. Leukemia. 2013 sep;27(9):1874-81. doi: 10.1038/leu.2013.163.

  15. Martín Pueyo G, Bello J. Policitemia vera. FMC. 2011;18(1):8-12.

  16. Amor A, Díaz C, Garrote H, Suárez Y, Fernández N, et al. Introducción del estudio molecular de la mutación JAK2V617F en neoplasias mieloproliferativas clásicas BCR-ABL negativas. Rev Cubana Hematol Inmunol Hemoter. 2013;29(4):398-406.

  17. Sonbol M, Firwana B, Zarzour A, Morad M, Rana V, et al. Comprehensive Review of JAK Inhibitors in Myeloproliferative Neoplasms. Ther Adv Hem. 2013 Feb;4(1):15-35. doi: 10.1177/2040620712461047.

  18. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010 Sep;363(12):1117– 1127. doi: 10.1056/NEJMoa1002028.

  19. Veneri D, Capuzzo E, de Matteis G, Franchini M, Baritono E, Benati M, et al. Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques. Blood Transfus. 2009 Jul;7(3):204-9.doi: 10.2450/2009.0070-08.

  20. Siemiatkowska A, Bieniaszewska M, Hellmann A, Limon J. JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms. Leuk Res. 2010 Mar;34(3):387–9. doi: 10.1016/j.leukres.2009.06.017

  21. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZFz. Leukemia. 2010 Jun;24(6):1128–38. doi:10.1038/leu.2010.69.

  22. Laughlin T, Moliterno A, Stein B, Rothberg P. Detection of Exon 12 Mutations in the JAK2 Gene Enhanced Analytical Sensitivity Using Clamped PCR and Nucleotide Sequencing. J Mol Diagn. 2010 May;12(3):278–82. doi:10.2353/jmoldx.2010.090177.

  23. Schnittger S, Bacher U, Haferlach C, Geer T, Müller P, et al. Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera. Haematologica 2009 Mar;94(3):414-8. doi:10.3324/haematol.13223.

  24. Pearson TC. Apparent polycythaemia. Blood Rev. 1991;5(4):205-13.

  25. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013 Sept;122(11):1881-6.

  26. Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, et al. Masked polycythemia Vera (mPV): Results of an international study. Am J Hematol.2014 Jan;89(1):52–4. doi:10.1002/ajh.23585.

  27. Johansson PL, Safai-Kutti S, Kutti J. An elevated venous haemoglobin concentration cannot be used as a surrogate marker for absolute erythrocytosis: A study of patients with polycythaemia vera and apparent polycythaemia. Br J Haematol; 2005 Jun;129(5):701–5.

  28. Lakey MA, Pardanani A, Hoyer JD, et al. Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations. Am J Clin Pathol. 2010 Jun;133(6):942-8. doi: 10.1309/AJCP3Z2AKUWRGTNM.

  29. Kvasnicka HM. WHO Classification of Myeloproliferative Neoplasms (MPN): A Critical Update. Curr Hematol Malig Rep. 2013;8:333– 41 DOI: 10.1007/s11899- 013-0186-x.




2020     |     www.medigraphic.com